Klotho protects chondrocyte viability via FOXO1/3 in osteoarthritis

Wei Wei*, Liefeng Ji, Wanli Duan, Jiang Zhu
Department of Orthopedics, Shaoxing Shangyu People's Hospital, Shaoxing, Zhejiang 312300, China

*For correspondence: Email: 13967580259@163.com; Tel: +86-013967580259

INTRODUCTION

Osteoarthritis (OA), is one of the most common types of joint disease. It is evidenced by lesions on cartilage tissue, joint synovium, subchondral bone, and other tissues. Cartilage degeneration is the result of a combination of factors, and is the most important pathological change in OA, which has a specific relationship with the viability of chondrocytes (CHs), inflammatory cytokines, and matrix metalloproteinases (MMPs) [1]. In the early stage of OA, the cartilage tissue swelling is caused by permeation. CHs then secrete inflammatory mediators such as interleukin-1 (IL-1) and MMPs, and the extracellular matrix (ECM) components begin to change [2]. During the development of OA, the increase of the inflammatory factors lead to the decline of CH viability, which is associated with the mediation of FOXO1 and FOXO3. These findings provide new insights into the treatment of OA.

Abstract

**Purpose:** To investigate the effect of Klotho and FOXO1/3 on the CH viability in OA.

**Methods:** The survival rate of CHs, Klotho and FOXO1/3 protein expression, and ROS production were measured in the OA cartilages of different degenerative phases. H$_2$O$_2$ was also used to injure CHs, and the cell viability, Klotho and FOXO1/3 expressions, as well as ROS levels were investigated to clarify the effect of exogenic Klotho on the injured CHs. Additionally, in order to verify the role of FOXO1/3 in Klotho-treated CHs, SOD2, GPX1, inflammatory factors, collagen II, SOX9, and Runx-2 levels were analyzed by silencing FOXO1 and FOXO3 expression via siRNA transfection.

**Results:** Klotho and FOXO1/3 expressions significantly decreased, and ROS production increased in severely human OA cartilage (p <0.05). Besides, H$_2$O$_2$ affected CHs viability with the suppression of Klotho and FOXO1/3 expression but ROS production was elevated. Exogenic Klotho application partly reversed the injury caused by H$_2$O$_2$. Furthermore, Klotho treatment of the injured CHs contributed to SOD2 and GPX1 expressions, and suppressed IL-1β, IL-6, TNF-α and MMP-13 production, resulting in the upregulation of collagen II and SOX9 as well as downregulation of collagen I and Runx-2. However, the protective effect of Klotho was weakened by FOXO1 and FOXO3 gene silencing.

**Conclusion:** Klotho protects CHs viability by suppressing oxidative stress and inflammation, which is associated with the mediation of FOXO1 and FOXO3. These findings provide new insights into the treatment of OA.

**Keywords:** Klotho, FOXO, Chondrocyte, Osteoarthritis, Oxidative stress
function, a further degradation of the ECM, and the weakening of the mechanical properties of the cartilage [3]. At the late OA stage, the cartilage becomes thin and vascularized, a large number of CHs die, and the ECM is severely damaged [4]. Therefore, the accumulation of the disabled CHs contributes to cartilage loss and gradually aggravates OA progression. Thus, maintaining CH activity is of considerable significance in delaying the progression of OA [5].

Klotho is an aging-related gene discovered by Kuro-o et al. [6] in a mouse aging model in 1997, and named after the goddess Klotho in ancient Greek mythology. Klotho is divided into membrane-bound Klotho and secretory Klotho, and they perform a variety of biological activities. On the one hand, membrane-bound Klotho acts as a receptor for fibroblast growth factor receptor 23 (FGF23), and mediates the biological activity of FGF23 in regulating the homeostasis of phosphorus metabolism [7]; and on the other hand, secreted Klotho is resistant to oxidative stress and inhibits inflammation and apoptosis in multiple cell types [8]. Klotho is involved in the occurrence and development of various diseases, such as vascular calcification, hypertension, kidney injury, diabetes, and tumors [9,10]. The association between Klotho and OA has already been confirmed in several studies. Gu et al. [11] found that Klotho deficiency causes cartilage damage in OA mice, and Klotho overexpression suppresses CH apoptosis. In addition, Chuchana et al. [12] discovered that secreted Klotho balances cartilage homeostasis by inhibiting the catabolic process.

The mechanism behind the protection of CHs from Klotho still remains unclear. The previous study suggests that Klotho protein strengthens the resistance to oxidative stress at both cellular and organismal levels, which is related to Forkhead box O (FOXO) activation. Therefore, Klotho and FOXO might have a similar effect on CHs. This study aims to elucidate the role of secreted Klotho and its downstream target, FOXO1/3, in the viability mediation of CHs, with the primary focus being on the anti-oxidative and anti-inflammatory manners.

**METHODS**

**OA tissue collection**

Articular cartilage tissue was collected from five patients (2 females, 3 males; average age: 61 years) with advanced OA and who have undergone knee arthroplasty. According to the location, the specimen was divided into three groups: the lateral epicondyle with lighter OA as the control area, the medial condyle with mild OA as the mild degeneration area, and the articular surface with severe OA as the severe degeneration area. This study was approved by the Ethics Committee of Shaoxing Shangyu People’s Hospital, and also followed international guidelines for human studies. Written, signed and informed consent was obtained from all participants before the study.

**Calcein AM/PI/Hoechst staining**

The surviving population of CHs was determined by Calcein AM and PI staining the ViaStain™ Calcein AM/PI/Hoechst Viability Kit (CSK-0118, Nexcelom Bioscience. Merrimack St, MA, USA). The living CHs were visible as green fluorescent, and dead CHs as red fluorescent. Besides, CHs were counterstained with Hoechst to enumerate the total number of nucleated CHs.

**Western blot (WB) analysis**

For protein isolation, the cartilage tissue was grinded with protein extraction buffer radioimmunoprecipitation assay (RIPA) and protease inhibitor phenylmethylsulfonyl fluoride (PMSF) (Beyotime, Shanghai, China) in order to extract the protein. Protein concentration was determined by utilizing the bicinchoninic acid (BCA) method (Beyotime, Shanghai, China). The protein was transferred by sodium dodecyl sulphate-polyacrylamide gel electrophoresis (SDS-PAGE) and then onto polyvinylidene fluoride (PVDF) membranes (Millipore, Billerica, MA, USA). The membrane was blocked with milk, incubated with the primary antibodies at 4°C overnight, and the secondary antibody at room temperature for 1 h. These antibodies were purchased from Abcam (Cambridge, MA, USA). The membrane was blocked with milk, incubated with the primary antibodies at 4°C overnight, and the secondary antibody at room temperature for 1 h. These antibodies were purchased from Abcam (Cambridge, MA, USA).

**CHs isolation and treatment**

The CHs from the three areas were cut into fragments and digested with 0.25% trypsin and type XI collagenase (Gibco, Waltham, MA, USA) for 12 h. The Cell pellets were filtered and re-suspended in Dulbecco’s modified eagle medium/F12 (DMEM/F12) containing 10 % fetal bovine serum (FBS) and 1% penicillin-streptomycin (Gibco, Waltham, MA, USA). CHs of the first generation were treated with H2O2 with or without recombinant human Klotho protein (ab84072, Abcam, Cambridge, MA, USA).
Immunofluorescence (IF)

The protein levels of SOD2 and GPX1 was ascertained using the IF method. Before staining, CHs were fixed with 4% paraformaldehyde and permeabilized with 0.1% Triton-X for 15 min., and were then treated with 5% bovine serum albumin (BSA) for 1 h at room temperature. Afterwards, CHs were washed with phosphate buffered saline (PBS), incubated with primary antibodies overnight at 4 °C and the secondary antibody at room temperature for 1 h. The first antibodies were purchased from Abcam (Cambridge, MA, USA), and the secondary antibody were from Invitrogen (Carlsbad, California, USA). The staining intensity was worked out using the ImageJ software.

siRNA transfection

The blocking of FOXO1 and FOXO3 gene expressions were performed using the siRNA transfection method, according to the Lipofectamine 2000 (Invitrogen, Carlsbad, California, USA) product instructions. CHs were incubated with the siRNA-transfection reagent mixture for 24 h, and then the medium was changed. siRNA targeting FOXO1 and FOXO3 was purchased from Thermo Fisher Scientific (106652; 115209. Waltham, MA, USA).

Real-time polymerase chain reaction (RT-PCR)

The RNA of CHs was extracted with TRIzol (Invitrogen, Carlsbad, California, USA) using conventional methods, and the purity of RNA was detected by NanoDrop; 1 μg of total RNA was taken for reverse-transcription into complementary deoxyribonucleic acid (cDNA) using one-step reverse transcription according to the manufacturer's instructions, and then performed in RT-PCR using SYBR Green Master (TOYOBO, Osaka, Japan). The primers used are shown in Table 1. Three replicates were made for each template. Glyceraldehyde 3-phosphate dehydrogenase (GAPDH) was used as an internal reference to calculate the 2^-ΔΔCt method.

Enzyme-linked immunosorbent assay (ELISA)

The levels of Klotho, FOXO1 and FOXO3 in CHs were determined using ELISA method (MBS2886510; MBS023752; MBS265005, San Diego, CA, USA) according to the manufacturer’s instructions.

Cell viability assay

CHs viability was ascertained using the cell counting kit 8 (CCK8) method (Beyotime, Shanghai, China) according to the manufacturer’s specifications. The intensity of the CCK8 product was measured at 450 nm using a microplate reader. Cell viability was presented as a percentage relative to the non-treated value.

Reactive oxygen species (ROS) assay

The total ROS in cartilage tissue and CHs was worked out using the ROS Detection Kit (PK-CA577-K936, Heidelberg, Germany), according to the kit protocol. The suspension of single-CH was analyzed on a plate reader for 3 replicates per condition. Relative fluorescence units (RFU) were detected using flow cytometry.

Statistical Analysis

The experimental data were statistically analyzed using Statistical Product and Service Solutions (SPSS) 18.0 (SPSS Inc., Chicago, IL, USA) and expressed as mean ± standard deviation (SD). A comparison amongst the various groups was carried out using the One-way ANOVA test, followed by Post Hoc Test (Least Significant Difference). P < 0. 05 was considered statistically significant.

Table 1: Primer sequences for RT-PCR

| Gene name | Forward (5’>3’) | Reverse (5’>3’) |
|-----------|----------------|----------------|
| Collagen I | GAGGGCCCAAGACGAAGACATC | CAGATCACGTCATCGCACAAC |
| Collagen II | TGGACGATCAGGCGAACC | GCTGCGGATGCTCTCAATCT |
| SOX9 | AGCGAACGCACATCAAGAC | CTGTAGGCGATCTGGTTGGG |
| Runx-2 | TGGTATTCTGTCATGGGCCGGTA | TCTCGATGGTGGGACATTTG |
| IL-1β | ATGATGGCTTATACAGTGGCAA | GTCGGAGATTCGTAGCTGGA |
| TNF-α | CCTCTCTTCTACTAGACGGCCTCG | GAGGACCTGGGATAGATGAG |
| IL-6 | ACTCACCCTCTCCAGAACTGGAAT | CCTCGATGGTGGGACATTTG |
| MMP-13 | ACTGAGAGGCTCCAGAAGATG | GAACCCCAGCATTTGGCTT |
| GAPDH | ACAACTTTGGTATCCTGGAAGG | GCCATCACGCCACAGTTTC |
RESULTS

Klotho and FOXO1/3 decreased in OA cartilage

In order to clarify the relationship between Klotho and OA, OA cartilage was collected and separated into three groups based on their surfaces. As shown in Figure 1 A, a cartilage with a flat, uniform, and transparent surface indicated a normal or slightly degenerate condition; the cartilage with a somewhat rough surface indicated a mildly degenerate state; and the cartilage with an extremely rough surface indicated a severely degenerated state. Furthermore, calcein AM/PI staining was used to determine the living CHs in the three states.

The result showed the surviving CHs significantly reduced as the cartilage got worse OA (Figure 1 B and C). Klotho, FOXO1, and FOXO3 protein were observed by WB, and it was found that all three proteins reduced gradually with the development of OA, especially the Klotho (Figure 1 D and E). As Klotho and FOXO have been stated to be capable of suppressing oxidative stress, the ROS production in the cartilage was measured by flow cytometry. As expected, the result indicated a higher ROS accumulation in the severely degenerated cartilage compared to the mild group, and much more than the control (Figure 1 F). Therefore, the findings suggest that the Klotho, FOXO1, and FOXO3 expressions were obviously reduced in the severely degraded cartilage. Further studies however need to be carried out on how klotho aids the survival of CHs.

Klotho and FOXO1/3 decreases in H$_2$O$_2$-treated CHs

To confirm that the expressions of Klotho and FOXO1/3 decreased with the CHs degeneration in vitro, H$_2$O$_2$ was used to trigger the injury of CHs. We cultured the CHs with different concentrations of H$_2$O$_2$ (100 to 400 µM) for 24 h, and harvested for analysis. As shown in the data in Figure 2 A, the Klotho content decreased under the H$_2$O$_2$ stimulation in a dose-dependent manner compared to the control. This was also the case with FOXO1 and the FOXO3 expression. The viability of CHs also significantly decreased due to the effects of H$_2$O$_2$ (Figure 2 B). As an inducer of oxidative stress, the ROS level was upregulated with the presence of H$_2$O$_2$ compared to the control group (Figure 2 C). The data here is convincing evidence that the content of Klotho and FOXO1/3 is suppressed in the degraded CHs.

Klotho protects H$_2$O$_2$-treated CHs survival and promotes FOXO1/3 expression

To determine whether Klotho could protect the CHs under the H$_2$O$_2$ stimulation, the CHs were treated with 200 µM H$_2$O$_2$ for 24 h and then the medium was exchanged with human-recombined Klotho protein (200 or 400 pM) for another 24 h treatment. The contents of Klotho, FOXO1, and FOXO3 were also measured using the ELISA method. These proteins were suppressed by H$_2$O$_2$, but the exogenic Klotho supplements reversed the effect of H$_2$O$_2$, which was very significant under a concentration of p400 pM (Figure 3 A). The stimulation of Klotho was also linked to the viability of CHs based on the result of the CCK assay, which was directly proportional to the number of living cells (Figure 3 B). In addition, the increased Klotho expression also played a role in the inhibition of ROS production when compared to the H$_2$O$_2$ treated CHs.
group, which also depended on the dose (Figure 3 C). The results above indicated that the H$_2$O$_2$ affected the viability of the CH, triggering the accumulation of ROS and the downregulation of Klotho, and FOXO1/3. However, the exogenic supplement of Klotho protein promoted the FOXO1 and FOXO3 expressions, which also protected the survival of CHs and suppressed the ROS production.

Figure 3: Klotho protects H$_2$O$_2$-treated CHs survival and promotes FOXO1/3 expression. (A) ELISA assay of Klotho, FOXO1, and FOXO3 level. (B) CCK8 assay of CHs viability. (C) Flow cytometry of ROS assay.

FOXO1/3 deficiency weakens the protection of Klotho on H$_2$O$_2$-treated CHs

Klotho significantly upregulated FOXO1 and FOXO3 expression. Hence, the FOXO1 and FOXO3 gene was silenced with siRNA transfection. After 24 h incubation with siRNA, the FOXO1 or FOXO3-silenced CHs were treated with H$_2$O$_2$ (100 to 400 µM) for another 24 h. As shown in Figure 4 A, the silencing of FOXO1 or FOXO3 did not weaken the viability of CHs in standard culture conditions. But the ability to withstand the damage by H$_2$O$_2$ was reduced in the silenced CHs. A similar situation happened in ROS production (Figure 4B). Compared to the control, the silenced CHs produced more ROS under the stimulation of H$_2$O$_2$, which was also dose-dependent.

Furthermore, Klotho protein was added in the FOXO1, or FOXO3-silenced CHs after the treatment of H$_2$O$_2$ (200 µM). The Klotho protein supplement upregulated the cellular Klotho content, increased FOXO3 levels in FOXO1 silenced CHs, and also elevated the FOXO1 levels in FOXO3-silenced CHs. However, the FOXO1 and FOXO3 levels were still low in each corresponding silenced-CHs (Figure 4C). As a result of FOXO1/3 silencing, the viable protection of Klotho in the H$_2$O$_2$-treated CHs decreased (Figure 4 D). Besides, FOXO1/3 deficiency also weakened the anti-ROS effect of Klotho, which was also significant when compared to the H$_2$O$_2$ alone group (Figure 4E). Therefore, the blocking of FOXO1 or FOXO3 affected the influence of Klotho with regards to the protection of cell viability and ROS suppression of CHs.

Figure 4: FOXO1/3 deficiency weakens the protection of Klotho. (A) CCK8 assay of CHs viability. (B) Flow cytometry of ROS assay. (*P < 0.05, **P < 0.01, ***P < 0.001 compared to Control) (C) ELISA assay of Klotho, FOXO1, and FOXO3 level. (D) CCK8 assay of CHs viability. (E) Flow cytometry of ROS assay. #P < 0.01, ###P < 0.001 compared to H$_2$O$_2$+Klotho)

Klotho suppresses ROS inflammation and production of H$_2$O$_2$-treated CHs via FOXO1/3

To further clarify the mechanism underlying the use of Klotho in the treatment of degradative CHs, the anti-oxidative enzymes, SOD2 and GPX1, the inflammation level, and the ECM metabolism-related gene mRNA expression were all analyzed. Compared to the control, H$_2$O$_2$ suppressed the SOD2 and GPX1 protein expression, which was partly recalled by Klotho stimuli. However, the silencing of FOXO1 or FOXO3 weakened the effect of Klotho again (Figure 5 A and B). H$_2$O$_2$ induced the upregulation of IL-1β, IL-6, TNF-α, and MMP-13, and Klotho played an inhibitory role in the inflammatory factor expression, which was also partly rejected by the deficiency of FOXO1 or FOXO3 (Figure 5 C). Besides this, the mRNAs of collagen II and SOX9 were upregulated, but collagen I and Runx-2 was downregulated due to Klotho stimuli applied to the H$_2$O$_2$ group. The silencing of FOXO1/3 also alleviates the function of Klotho in this gene expression. Therefore, it can be concluded that Klotho prevent H$_2$O$_2$ induced CHs injury by increasing the anti-oxidative stress and anti-inflammation ability with the mediation of ECM balance, which was partly based on the presence of FOXO1 and FOXO3.
DISCUSSION

Chondrocytes (CHs) are terminally differentiated cells with weak proliferation abilities. When the CH viability decreases, the anabolic capacity gradually decreases, and the ability to respond to growth factors, such as anabolic factors, gradually declines. It lacks the ability to synthesize sufficient cartilage matrix needed to maintain cartilage volume and cartilage structure [13]. In a healthy cartilage, the metabolism of the matrix is strictly regulated to maintain a balance between synthesis and degradation, which is generally believed to be broken when OA occurs [14]. During OA, degradation and synthesis usually increase together. Through anabolic metabolism, CHs attempt to repair the damaged ECM. Due to the effects of various matrix MMPs and specific cytokines, the cartilage matrix is degraded, the synthesis is inhibited, and then the cartilage destruction is intensified. In some areas, the rate of biosynthetic metabolism cannot keep up with the speed of catabolic metabolism, resulting in cartilage degeneration [15].

The decrease in functional CHs may be one of the reasons leading to reduced synthesis of cartilage matrix, increased degradation, and finally cartilage degeneration. In this study, Klotho is deemed adequate in supporting the viability of CHs in the oxidative injury condition. In the meantime, it also plays a role in anti-inflammatory action. Therefore, Klotho enhances the population of functional CHs as well as ECM stability, which is reflected in the maintenance of type II collagen and SOX9, and reduction of collagen I and Runx-2. The healthy cartilage matrix is mainly composed of collagen II, water, and proteoglycans. SOX9 is also known as a transcription factor that is vital for CH differentiation and cartilage formation [16]. Whereas, the different or degraded CHs express more type I collagen and Runx-2 [17].

Oxidative stress not only damages the cartilage matrix, it also injures the biofilm, proteins, and nucleic acids of CH, resulting in changes to the morphology, growth status, and function of the CHs. Redundant ROS leads to a considerable reduction of CHs survival, leading to the atrophy and thinning of articular cartilage which are essential mechanisms of OA [18,19]. The relationship between Klotho gene and oxidative stress has been studied for a long time. Padanilam et al [20] found that in H2O2-induced oxidative stress in a mouse’s kidney; the expression of Klotho was reduced, and the apoptosis of renal collecting duct cells increased, which makes Klotho fit for use as an indicator of tissue apoptosis under oxidative stress. In addition, Klotho is efficient in the removal of ROS and confers oxidative stress resistance [21]. FOXO belongs to a class of transcription factors involved in the regulation of oxidative stress, as well as the modulation of the downstream gene targets in CHs or CHs’ activity. Amongst the three principal membranes, FOXO1 and FOXO3 are found in both bone and cartilage [22]. Klotho can suppress oxidative stress by up-regulating FOXO. Lim et al [23] reported that Klotho protects oxidative stress by enhancing FOXO3-mediated MnSOD expression. Similar to what this study discovered, Akasaki et al [24] proposed that the silencing of FOXO1/3 affects CHs viability, accompanied by increased apoptosis. However, whether Klotho prevents CHs from ROS-induced injury by the upregulation of FOXO1 and FOXO3 has not been previously reported. Experimental findings so far provide convincing evidence that Klotho and its downstream target FOXO1/3 play a crucial role in the OA process.

CONCLUSION

Klotho has shown remarkable protective effects on CHs, oxidative injuries and inflammation, due to the upregulation of FOXO1 and FOXO3. The findings also show that the secreted Klotho can be a target that interrupts the disability of CHs, through the application of a deep understanding of Klotho and FOXO in OA treatment. These findings provide new insights into the treatment of OA.
DECLARATIONS

Conflict of interest

No conflict of interest is associated with this work.

Contribution of authors

We declare that this work was done by the authors named in this article and all liabilities pertaining to claims relating to the content of this article will be borne by the authors.

Open Access

This is an Open Access article that uses a funding model which does not charge readers or their institutions for access and distributed under the terms of the Creative Commons Attribution License (http://creativecommons.org/licenses/by/4.0) and the Budapest Open Access Initiative (http://www.budapestopenaccessinitiative.org/road), which permit unrestricted use, distribution, and reproduction in any medium, provided the original work is properly credited.

REFERENCES

1. Hunter DJ, Bierma-Zeinstra S. Osteoarthritis. Lancet 2019; 393(10182): 1745-1759.

2. Iijima H, Aoyama T, Tajino J, Nagai M, Zhang X, Yamaguchi S, Akiyama H, Kuroki H. Destabilization of the medial meniscus leads to subchondral bone defects and site-specific cartilage degeneration in an experimental rat model. Osteoarthritis Cartilage 2014; 22(7): 1036-1043.

3. Mobasheri A, Kalamegam G, Musumeci G, Batt ME. Chondrocyte and mesenchymal stem cell-based therapies for cartilage repair in osteoarthritis and related orthopaedic conditions. Maturitas 2014; 78(3): 188-198.

4. Li G, Yin J, Gao J, Cheng TS, Pavlos NJ, Zhang C, Zheng MH. Subchondral bone in osteoarthritis: insight into risk factors and microstructural changes. Arthritis Res Ther 2013; 15(6): 223.

5. Vinatier C, Merceron C, Guicheux J. Osteoarthritis: from pathogenetic mechanisms and recent clinical developments to novel prospective therapeutic options. Drug Discov Today 2018; 21(12): 1932-1937.

6. Nagai T, Yamada K, Kim HC, Kim YS, Noda Y, Imura A, Nabeshima Y, Nabeshima T. Cognition impairment in the genetic model of aging klotho gene mutant mice: a role of oxidative stress. Faseb J 2003; 17(1): 50-52.

7. Olauson H, Vervloet MG, Cozzolino M, Massy ZA, Urena TP, Larsson TE. New insights into the FGFR23-Klotho axis. Semin Nephrol 2014; 34(6): 586-597.

8. Nagai T, Yamada K, Kim HC, Kim YS, Noda Y, Imura A, Nabeshima Y, Nabeshima T. Cognition impairment in the genetic model of aging klotho gene mutant mice: a role of oxidative stress. Faseb J 2003; 17(1): 50-52.

9. Zou D, Wu W, He Y, Ma S, Gao J. The role of klotho in chronic kidney disease. Bmc Nephrol 2018; 19(1): 285.

10. Silva AP, Mendes F, Cariaes E, Gonçalves RB, Fragoso A, Dias C, Tavares N, Cape HM, Santos N, Rato F, et al. Plasmatic Klotho and FGFR23 Levels as Biomarkers of CKD-Associated Cardiac Disease in Type 2 Diabetic Patients. Int J Mol Sci 2019; 20(7): 1536.

11. Gu Y, Ren K, Jiang C, Wang L, Yao Q. Regulation of cartilage damage caused by lack of Klotho with thioredoxin/peroxiredoxin (Trx/Prx) system and succedent NLCP3 activation in osteoarthritis mice. Am J Transl Res 2019; 11(12): 7338-7350.

12. Chuchana P, Mausset-Bonnefont AL, Mathieu M, Espinoza F, Teigell M, Toupet K, Ripoll C, Djouad F, Noel D, Jorgensen C, et al. Secreted alpha-Klotho maintains cartilage tissue homeostasis by repressing NOS2 and ZIP8-MMP13 catabolic axis. Aging (Albany NY) 2018; 10(6): 1442-1453.

13. Sandell LJ, Aigner T. Articular cartilage and changes in arthritis. An introduction: cell biology of osteoarthritis. Arthritis Res 2001; 3(2): 107-113.

14. Lotz M, Losser RF. Effects of aging on articular cartilage homeostasis. Bone 2012; 51(2): 241-248.

15. Courties A, Gualillo O, Berenbaum F, Sellam J. Metabolic stress-induced joint inflammation and osteoarthritis. Osteoarthritis Cartilage 2015; 23(11): 1955-1965.

16. Bi W, Deng JM, Zhang Z, Behringer RR, de Crombrugghe B. Sox9 is required for cartilage formation. Nat Genet 1999; 22(1): 85-89.

17. Machida T, Nishida K, Nasu Y, Nakahara R, Ozawa M, Harada R, Horita M, Takeshita A, Kaneda D, Yoshida A, et al. Inhibitory effect of JAK inhibitor on mechanical stress-induced protease expression by human articular chondrocytes. Inflamm Res 2017; 66(11): 999-1009.

18. Collins JA, Diekman BO, Losser RF. Targeting aging for disease modification in osteoarthritis. Curr Opin Rheumatol 2018; 30(1): 101-107.

19. Lepetsos P, Papavassiliou AG. ROS/oxidative stress signaling in osteoarthritis. Biochim Biophys Acta 2016; 1862(4): 576-591.

20. Padanilam BJ. Cell death induced by acute renal injury: a perspective on the contributions of apoptosis and necrosis. Am J Physiol Renal Physiol 2003; 284(4): F608-F627.

21. Yamamoto M, Clark JD, Pastor JV, Gurnani P, Nandi A, Kurosu H, Miyoshi M, Ogawa Y, Castrillon DH, Rosenblatt KP, et al. Regulation of oxidative stress by the anti-aging hormone klotho. J Biol Chem 2005; 280(45): 38029-38034.

22. Zhang C, Feinberg D, Alharbi M, Ding Z, Lu C, O’Connor JP, Graves DT. Chondrocytes Promote Vascularization in Fracture Healing Through a FOXO1-Dependent Mechanism. J Bone Miner Res 2019; 34(3): 547-556.
23. Lim SW, Jin L, Luo K, Jin J, Shin YJ, Hong SY, Yang CW. Klotho enhances FoxO3-mediated manganese superoxide dismutase expression by negatively regulating PI3K/AKT pathway during tacrolimus-induced oxidative stress. Cell Death Dis 2017; 8(8): e2972.

24. Akasaki Y, Alvarez-Garcia O, Saito M, Carames B, Iwamoto Y, Lotz MK. FoxO transcription factors support oxidative stress resistance in human chondrocytes. Arthritis Rheumatol 2014; 66(12): 3349-3358.